Rafferty Asset Management, LLC Innoviva, Inc. Transaction History

Rafferty Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $49,145 - $64,426	-4,233 Reduced 27.27%	11,291 $131,000
Q2 2022 Aug 12, 2022	BUY	$14.32 - $19.88 $222,303 - $308,617	15,524 New	15,524 $229,000
Q1 2022 May 13, 2022	SELL	$15.39 - $20.25 $194,544 - $255,980	-12,641 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$15.91 - $18.72 $36,911 - $43,430	2,320 Added 22.48%	12,641 $218,000
Q3 2021 Nov 10, 2021	BUY	$13.06 - $17.24 $134,792 - $177,934	10,321 New	10,321 $172,000
Q3 2019 Nov 14, 2019	SELL	$10.05 - $14.55 $182,628 - $264,402	-18,172 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$13.1 - $14.95 $238,053 - $271,671	18,172 New	18,172 $265,000

227

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.24B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.